Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 142380
Corporate User License Price USD 6000
Corporate User License Price INR 427140
Site License Price USD 4000
Site License Price INR 284760
Request a Quote

Report Title

Muscle Atrophy - Pipeline Review, H2 2018

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Muscle Atrophy - Pipeline Review, H2 2018


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Muscle Atrophy - Pipeline Review, H2 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Muscle Atrophy - Pipeline Review, H2 2018



Executive Summary

Muscle Atrophy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Atrophy-Pipeline Review, H2 2018, provides an overview of the Muscle Atrophy (Musculoskeletal Disorders) pipeline landscape.

Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy and arthritis. Treatment includes exercise, dietary changes and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscle Atrophy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Atrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Unknown stages are 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Muscle Atrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Atrophy (Musculoskeletal Disorders).

- The pipeline guide reviews pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Muscle Atrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Muscle Atrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Muscle Atrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscle Atrophy-Overview

Muscle Atrophy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Muscle Atrophy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscle Atrophy-Companies Involved in Therapeutics Development

Fate Therapeutics Inc

Igenomix SL

K-Stemcell Co Ltd

Milo Biotechnology LLC

Shionogi & Co Ltd

Spherium Biomed SL

Teijin Pharma Ltd

Muscle Atrophy-Drug Profiles

AAV9-Follistatin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EMMY-105-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EMMY-106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-4039-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HSD11B1 for Muscle Atrophy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-15028-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Parry-Romberg disease and Thromboangiitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscle Atrophy-Dormant Projects

Muscle Atrophy-Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Muscle Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Muscle Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Muscle Atrophy-Pipeline by Fate Therapeutics Inc, H2 2018

Muscle Atrophy-Pipeline by Igenomix SL, H2 2018

Muscle Atrophy-Pipeline by K-Stemcell Co Ltd, H2 2018

Muscle Atrophy-Pipeline by Milo Biotechnology LLC, H2 2018

Muscle Atrophy-Pipeline by Shionogi & Co Ltd, H2 2018

Muscle Atrophy-Pipeline by Spherium Biomed SL, H2 2018

Muscle Atrophy-Pipeline by Teijin Pharma Ltd, H2 2018

Muscle Atrophy-Dormant Projects, H2 2018

Muscle Atrophy-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Fate Therapeutics Inc

Igenomix SL

K-Stemcell Co Ltd

Milo Biotechnology LLC

Shionogi & Co Ltd

Spherium Biomed SL

Teijin Pharma Ltd

Muscle Atrophy Therapeutic Products under Development, Key Players in Muscle Atrophy Therapeutics, Muscle Atrophy Pipeline Overview, Muscle Atrophy Pipeline, Muscle Atrophy Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person